Clinical Trial Update: Filgotinib Versus Placebo in Adults With Active Rheumatoid Arthritis (RA) Who Have an Inadequate Response to Biologic Disease-modifying Anti-rheumatic Drug(s) (DMARDs) Treatment [Phase 3]

View source ↗

Summary

Phase 3 trial assessing filgotinib versus placebo in adults with active rheumatoid arthritis after inadequate response to biologic DMARDs; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• Filgotinib (filgotinib)

Snippet

Sponsor: Gilead Sciences | Conditions: Rheumatoid Arthritis | Phase 3 | Status: COMPLETED | Results posted: 2021-01-15